h-header

news

News dal mondo

27

Nov

Antitrust: Commission fines Teva and Cephalon €60.5 million for delaying entry of cheaper generic medicine

The European Commission has fined the pharmaceutical companies Teva and Cephalon €60.5 million for agreeing to delay for several years the market entry of a cheaper generic version of Cephalon's drug for sleep disorders, modafinil, after Cephalon's main patents had expired. The agreement was concluded well before Cephalon became a subsidiary of Teva. The agreement violated EU antitrust rules and caused substantial harm to EU patients and healthcare systems by keeping prices high for modafinil....[EU]

slider-banner

h-footer
pager